ATE526032T1 - Stabilisierte flüssige interferon-formulierungen - Google Patents

Stabilisierte flüssige interferon-formulierungen

Info

Publication number
ATE526032T1
ATE526032T1 AT04820468T AT04820468T ATE526032T1 AT E526032 T1 ATE526032 T1 AT E526032T1 AT 04820468 T AT04820468 T AT 04820468T AT 04820468 T AT04820468 T AT 04820468T AT E526032 T1 ATE526032 T1 AT E526032T1
Authority
AT
Austria
Prior art keywords
interferon
formulations
stabilized liquid
cyclodextrin
room temperature
Prior art date
Application number
AT04820468T
Other languages
English (en)
Inventor
Curto Maria Del
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of ATE526032T1 publication Critical patent/ATE526032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04820468T 2003-12-11 2004-12-10 Stabilisierte flüssige interferon-formulierungen ATE526032T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104646 2003-12-11
EP04103349 2004-07-13
PCT/EP2004/053407 WO2005058346A1 (en) 2003-12-11 2004-12-10 Stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
ATE526032T1 true ATE526032T1 (de) 2011-10-15

Family

ID=34702349

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04820468T ATE526032T1 (de) 2003-12-11 2004-12-10 Stabilisierte flüssige interferon-formulierungen

Country Status (18)

Country Link
US (1) US7846427B2 (de)
EP (1) EP1691825B1 (de)
JP (1) JP4658961B2 (de)
AT (1) ATE526032T1 (de)
AU (1) AU2004298781B2 (de)
BR (1) BRPI0416980A (de)
CA (1) CA2547822A1 (de)
CY (1) CY1112193T1 (de)
DK (1) DK1691825T3 (de)
ES (1) ES2374530T3 (de)
HR (1) HRP20110699T1 (de)
IL (1) IL176021A0 (de)
NO (1) NO20063108L (de)
PL (1) PL1691825T3 (de)
PT (1) PT1691825E (de)
RS (1) RS52218B (de)
SI (1) SI1691825T1 (de)
WO (1) WO2005058346A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
JP2007538048A (ja) * 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2170268A2 (de) 2007-06-25 2010-04-07 Amgen, Inc. Zusammensetzungen von spezifischen bindungsmitteln für den hepatozyten-wachstumsfaktor
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
US20100203014A1 (en) * 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
EA201590790A1 (ru) 2012-10-26 2015-08-31 Люпин Лимитед СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
BR112020005703A2 (pt) 2017-09-27 2020-10-20 Novartis Ag formulação parentérica compreendendo siponimod
CN111494611A (zh) * 2020-06-08 2020-08-07 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
RU2004102500A (ru) * 2001-06-29 2005-04-10 Максиген Апс (Dk) Композиции интерферонов
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
JP2007538048A (ja) 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
JP4988562B2 (ja) 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤

Also Published As

Publication number Publication date
NO20063108L (no) 2006-07-04
EP1691825A1 (de) 2006-08-23
US7846427B2 (en) 2010-12-07
PL1691825T3 (pl) 2012-02-29
CA2547822A1 (en) 2005-06-30
SI1691825T1 (sl) 2011-12-30
JP2007513925A (ja) 2007-05-31
AU2004298781B2 (en) 2010-04-01
DK1691825T3 (da) 2011-12-05
ES2374530T3 (es) 2012-02-17
WO2005058346A1 (en) 2005-06-30
CY1112193T1 (el) 2015-12-09
JP4658961B2 (ja) 2011-03-23
PT1691825E (pt) 2011-10-12
RS52218B (en) 2012-10-31
AU2004298781A1 (en) 2005-06-30
IL176021A0 (en) 2006-10-05
HRP20110699T1 (hr) 2011-10-31
BRPI0416980A (pt) 2007-02-21
EP1691825B1 (de) 2011-09-28
US20070104682A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
NO20063108L (no) Stabiliserte, flytende interferonformuleringer
ES2418833T3 (es) Formulaciones líquidas de interferón estabilizadas
DE502004012418D1 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
CY1115233T1 (el) Υγρα σταθεροποιημενα σκευασματα ιντερφερονης-βητα σε επικαλυμμενους περιεκτες φαρμακευτικης χρησης
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
CA2304808A1 (en) Liquid interferon-.beta. formulations
BRPI0410488A (pt) composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa'
HUP0302311A2 (hu) Gyógyászati aeroszol-készítmények
ATE275974T1 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
AR017066A1 (es) Cristales de glicoproteina, de enlazamiento cruzado con carbohidrato
JP4871720B2 (ja) 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
KR101699677B1 (ko) 고나도트로핀을 위한 제제
CO4830457A1 (es) Preparados efervescentes
JP2008050320A (ja) インターフェロン−β含有医薬組成物
DE60134883D1 (de) Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
RU2238758C2 (ru) Водный раствор интерферона-альфа-два человека для инъекций
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1691825

Country of ref document: EP